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Abstract
Introduction: Joint fluid in patients with Lyme arthritis often contains high levels of CCL4 and CCL2, which are
chemoattractants for monocytes and some T cells, and CXCL9 and CXCL10, which are chemoattractants for CD4+
and CD8+ T effector cells. These chemokines are produced primarily by cells of monocyte lineage in TH1-type
immune responses. Our goal was to begin to learn how infection with Borrelia burgdorferi leads to the secretion of
these chemokines, using patient cell samples. We hypothesized that B. burgdorferi stimulates chemokine secretion
from monocytes/macrophages in multiple ways, thereby linking innate and adaptive immune responses.
Methods: Peripheral blood mononuclear cells (PBMC) from 24 Lyme arthritis patients were stimulated with B.
burgdorferi, interferon (IFN)-g, or both, and the levels of CCL4, CCL2, CXCL9 and CXCL10 were measured in culture
supernatants. CD14+ monocytes/macrophages from PBMC and synovial fluid mononuclear cells (SFMC) were
stimulated in the same way, using available samples. CXCR3, the receptor for CXCL9 and CXCL10, and CCR5, the
receptor for CCL4, were assessed on T cells from PBMC and SFMC.
Results: In patients with Lyme arthritis, B. burgdorferi but not IFN-g induced PBMC to secrete CCL4 and CCL2, and
B. burgdorferi and IFN-g each stimulated the production of CXCL9 and CXCL10. However, with the CD14+ cell
fraction, B. burgdorferi alone stimulated the secretion of CCL4; B. burgdorferi and IFN-g together induced CCL2
secretion, and IFN-g alone stimulated the secretion of CXCL9 and CXCL10. The percentage of T cells expressing
CXCR3 or CCR5 was significantly greater in SFMC than PBMC, confirming that TH1 effector cells were recruited to
inflamed joints. However, when stimulated with B. burgdorferi or IFN-g, SFMC and PBMC responded similarly.
Conclusions: B. burgdorferi stimulates PBMC or CD14+ monocytes/macrophages directly to secrete CCL4, but
spirochetal stimulation of other intermediate cells, which are present in PBMC, is required to induce CD14+ cells to
secrete CCL2, CXCL9 and CXCL10. We conclude that B. burgdorferi stimulates monocytes/macrophages directly and
indirectly to guide innate and adaptive immune responses in patients with Lyme arthritis.
Introduction
In the US, Lyme arthritis, which is caused by the tick-
borne spirochete Borrelia burgdorferi,u s u a l l yb e g i n s
with an expanding skin lesion, erythema migrans (EM)
[1]. Months later, untreated patients often develop inter-
mittent or persistent arthritis in a few large joints for a
period of several years [2]. In EM lesions, perivascular
infiltrates of macrophages and CD4
+ and CD8
+ T cells
are found along with small numbers of B cells and
plasma cells [3,4]. Similarly, in synovial lesions, macro-
phages and CD4
+ and CD8
+ T cells are the primary
infiltrating cells, sometimes accompanied by clusters of
B cells and plasma cells [5,6]. Thus, cells involved in
innate and adaptive immune responses are present at
sites of Borrelia infection early and late in the illness.
Chemokines (chemotactic cytokines) play a crucial
role in the homing of inflammatory cells to infected tis-
sues [7-9]. Early pathogen-induced release of CCL3 and
CCL4 by innate immune cells, such as dendritic cells
and macrophages, is vital for the initial influx of inflam-
matory cells [7-9]. Dendritic cells activated by innate sti-
muli migrate to regional lymph nodes, where they
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(TH1 ) - l i k ei m m u n er e s p o n s e s ,activated T cells upregu-
late CXCR3, and macrophage-derived, interferon-
gamma (IFN-g)-inducible chemokines, such as CXCL9
and CXCL10, which are ligands for CXCR3, attract acti-
vated T cells into inflamed tissues [7-9]. Thus, chemo-
kines have a critical role in bringing together innate and
adaptive immune responses.
Previous studies in Lyme disease clearly show that B.
burgdorferi induces primarily a TH1-type immune
response [10-13], leading to the secretion of cytokines
and chemokines associated with activation of cells of
monocyte lineage. In a study of mRNA expression of 8
cytokines and 12 chemokines in EM skin lesions, there
was a predominance of IFN-g and the IFN-g-inducible
chemokines CCL2, CXCL9, and CXCL10 [4]. Similarly,
in a study of the protein levels of 7 cytokines and 7 che-
mokines in joint fluid in patients with Lyme arthritis,
high levels of IFN-g and CCL2, CCL4, CXCL9, and
CXCL10 were found [14]. CCL2 and CCL4 are che-
moattractants for monocytes and some T cells, and
CXCL9 and CXCL10 are chemoattractants for CD4
+
and CD8
+ T effector cells [8]. The prominence of these
chemokines at sites of infection in Lyme disease corre-
lates well with the types of cells found in infected tissues
and fluids [4,14]. However, it is not yet clear how B.
burgdorferi stimulates the secretion of these chemokines.
In the present study, our goal was to begin to learn
how infection with B. burgdorferi stimulates monocytes/
macrophages to secrete CCL2, CCL4, CXCL9, and
CXCL10. For this purpose, we measured the levels of
these chemokines in culture supernatants after B. burg-
dorferi or IFN-g stimulation of peripheral blood mono-
nuclear cells (PBMCs), CD14
+ cells from PBMCs, or
synovial fluid mononuclear cells (SFMCs) from patients
with Lyme arthritis and normal control subjects. We
hypothesized that B. burgdorferi stimulates chemokine
secretion from monocytes/macrophages in multiple
ways, thereby linking innate and adaptive immune
responses.
Materials and methods
Study population
For this study, which was carried out in 2007, frozen
PBMCs were tested from 24 Lyme arthritis patients in
whom large numbers of cells were available. Concomi-
tant SFMCs were also available in 11 of the 24 patients.
In the few patients in whom samples were obtained on
more than one date, the first date was used for testing.
The 24 patients were seen over a 12-year period, from
September 1994 through January 2007. In initial experi-
ments, frozen PBMCs that were collected from 4 normal
control subjects from June 2006 through March 2007
were also tested. We used frozen cells from normal
subjects so that the cells would be comparable with
those from patients.
All patients met the Centers for Disease Control and
Prevention criteria for the diagnosis of Lyme disease
[15] and were entered into a study called ‘Immunity in
Lyme Arthritis’. The patients were treated with antibio-
tic therapy in accordance with the guidelines of the
Infectious Diseases Society of America [16]. The Human
Investigations Committees at Tufts Medical Center
(Boston, MA, USA) (1987 to 2002) and Massachusetts
General Hospital (2002 to 2009) approved the study,
and all patients (or the parents of patients who were
minors) provided written informed consent.
B. burgdoferi or IFN-g stimulation of PBMCs, CD14
+ cells,
or SFMCs
On the day of testing, frozen PBMCs (5 × 10
6 cells/mL)
or SFMCs from patients or normal control subjects
were thawed in a 37°C water bath and washed with 50
mL of phosphate-buffered saline (PBS). The viable cells
were counted using trypan blue exclusion. The average
yields of viable cells were 62% (range of 40% to 90%)
from patient samples and 59% (range of 47% to 70%)
from normal subjects. With PBMCs, 1 × 10
6 cells were
set aside for stimulation; in patients in whom enough
cells were available, the remaining cells were used for
isolation of CD14
+ monocytes/macrophages with mag-
netic-activated cell sorting (MACS) columns (Miltenyi
Biotec Inc., Auburn, CA, USA) in accordance with the
instructions of the manufacturer. Briefly, cells were sus-
pended in 50 mL of MACS buffer (PBS, 0.5% bovine
serum albumin, and 2 mM EDTA [ethylenediaminete-
traacetic acid]) and were labeled with primary antigen-
presenting cell (APC)-conjugated CD14 antibody (BD
Biosciences, San Jose, CA, USA) and incubated with
MACS anti-APC microbeads (Miltenyi Biotec Inc.). The
CD14
+ cells bound with anti-APC microbeads were iso-
lated using a magnetic separation column (Miltenyi Bio-
tec Inc.).
The average yields of CD14
+ cells were 11% (range of
3% to 30%) from the PBMCs of patients and 20% (range
of 4% to 32%) from those of normal controls. These
percentages from frozen cells were similar to the pro-
portion of CD14
+ cells (14% ± 3%) recovered from fresh
PBMCs in a previous study [17]. In two control subjects
in whom sufficient cells were collected, flow cytometric
analysis showed that CD14
+ cells made up, respectively,
82% and 90% of this cell fraction. Because of limited cell
numbers, fluorescence-activated cell sorting (FACS) ana-
lysis to determine the proportion of monocytes and
macrophages in the CD14
+ cell fraction was not done,
and CD14
+ cells were not isolated from SFMCs.
Whole PBMCs (2 × 10
5 cells per well), CD14
+
cells from PBMCs (4 × 10
4 cells per well), or SFMCs
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5 cells per well) were suspended in cell culture
medium (RPMI, 1% HEPES, 10% human serum, and 1%
glutamine) and plated singly in 96-well culture plates
(Corning Incorporated, Corning, NY, USA). The num-
ber of spirochetes per milliliter of culture was deter-
mined using spectrophotometry of spirochetal DNA, as
previously described [18]. Live B. burgdorferi was used
in all experiments.
To determine optimal culture conditions for the sti-
mulation of chemokine secretion, PBMCs from 6 nor-
mal control subjects were stimulated with multiplicities
of infection (MOIs) ranging from 6 to 500 spirochetes
per host cell with durations of incubation ranging from
4 to 120 hours. Although similar results were seen with
MOIs from 6 to 100 for all four chemokines, the highest
secretion of CCL4 occurred with an MOI of 50. Secre-
tion of CCL4 increased steadily during 5 days in culture,
but secretion of CXCL9 and CXCL10 did not appear
until the fifth day. This suggested that stimulated cells
were viable throughout the 5 days in culture. On the
basis of these preliminary findings, cells were incubated
with B. burgdorferi (strain EM70, an OspC type A strain,
MOI of 50), IFN-g (50 ng), or B. burgdorferi and IFN-g
at 37°C in 5% CO2 for 5 days.
After incubation, protein levels of CXCL9, CXCL10,
CCL2, and CCL4 were determined in cell culture super-
natants using cytometric bead array, according to the
instructions of the manufacturer (BD Biosciences).
Briefly, microbeads precoated with capture antibodies
for each chemokine were mixed together in groups and
incubated with culture supernatants diluted in sample
buffer. Supernatants of PBMCs or SFMCs that had been
incubated alone were diluted 5-fold with sample buffer,
and cells that had been incubated with B. burgdorferi or
IFN-g were diluted 50-fold with this buffer.
Expression of CXCR3 and CCR5 on T cells in PBMCs or
SFMCs
After the collection of supernatants, non-adherent cells
were resuspended and collected to determine the
expression of CXCR3 or CCR5 and T cells in PBMCs or
SFMCs. Harvested cells were washed with FACS buffer
(PBS, 1% fetal bovine serum, and 0.1% Na Azide) and
stained with the antibodies specific for CD3 (APC; BD
Biosciences), CD4 (PerCP; BD Biosciences), CXCR3
(FITC; BD Biosciences), or CCR5 (PE; BD Biosciences).
The cell surface expression of these receptors was ana-
lyzed by flow cytometry with a FACSCalibur (BD
Biosciences).
Statistics
Secretion of chemokines and chemokine receptor
expression were compared between groups by Mann-
Whitney rank sum test. Chemokine data were correlated
with the length of time that the cells were frozen, using
Pearson correlation test. As a correction for multiple
variables, P values of not more than 0.01 were consid-
ered statistically significant.
Results
Description of patients with Lyme arthritis
The 24 patients with Lyme arthritis, who were represen-
tative of our previously published cohort of 117 patients
with this type of arthritis [19], had a median age of 36
years (range of 12 to 67 years); 17 were male and 7
were female. The diagnosis of Lyme arthritis was usually
made within 1 to 4 weeks after the onset of knee swel-
ling. Eleven of the 24 patients (46%) were first seen
prior to the initiation of antibiotic therapy, 10 were first
evaluated during 1- to 4-month courses of oral or intra-
venous (i.v.) antibiotic treatment, and 3 were not seen
until the post-antibiotic period, 7 to 11 months after the
start of antibiotics. At their first visit, 13 of the 24
patients (54%) had a positive polymerase chain reaction
( P C R )r e s u l tf o rB. burgdorferi DNA in joint fluid. Of
the 13 patients, 6 were seen prior to antibiotic treatment
and 7 were evaluated during antibiotic therapy. Seven of
the 24 patients had the resolution of arthritis within 3
months after the initiation of antibiotics, defined as anti-
biotic-responsive arthritis, whereas the remaining 17
patients had persistent arthritis for more than 3 months
after at least 8 weeks of oral antibiotics or at least 4
weeks of i.v. antibiotics or both, defined as antibiotic-
refractory arthritis [19]. This distribution of refractory
and responsive cases is reflective of our role as a referral
center.
Chemokine analysis according to clinical parameters
The chemokine data from cell cultures were compared
in patients seen before, during, or after antibiotic ther-
apy, in those with positive or negative PCR results for B.
burgdorferi DNA in joint fluid, and in those with anti-
biotic-responsive or antibiotic-refractory arthritis.
Although B. burgdorferi-stimulated PBMCs from
patients with positive PCR results tended to secrete
higher levels of CCL2 and CXCL9 in culture than
PBMCs from patients with negative PCR results, none
of the differences between the groups was statistically
significant. In addition, since patients’ cells had been
stored for as long as 12 years, the chemokine data were
analyzed according to the length of time that the cells
had been frozen, but no correlation was found. Because
timing of cell collection, PCR results, and duration of
freezing did not result in differences in chemokine
secretion ex vivo, the data from all 24 patients are pre-
sented together here.
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stimulated PBMCs and CD14
+ monocytes/macrophages
from normal control subjects
In initial experiments, PBMC sw e r ef i r s tt e s t e df r o m4
healthy control subjects from the laboratory. Unstimu-
lated PBMCs from control subjects secreted only basal
levels of CCL4, CCL2, CXCL9, or CXCL10 during 5
days in culture (Figure 1a). With B. burgdorferi stimula-
tion, the levels of each of the four chemokines tended to
be higher; with IFN-g stimulation, the levels of CCL2,
CXCL9, and CXCL10 tended to be greater, and there
was no additive effect from stimulation with B. burgdor-
feri and IFN-g together. However, differences in chemo-
kine secretion among stimulated or unstimulated cells
were not statistically significant.
As with PBMCs, unstimulated CD14
+ monocytes/
macrophages secreted only basal levels of the four che-
mokines in culture (Figure 1b). In several cases,
B. burgdorferi alone induced CD14
+ cells to secrete
small amounts of CCL4; B. burgdorferi and IFN-g
together stimulated CCL2 secretion, and IFN-g seemed
to induce CXCL9 and CXCL10 secretion. However, as
with PBMCs, the differences between stimulated and
unstimulated cells were not statistically significant
(Figure 1a, b).
Chemokine secretion by B. burgdorferi- or IFN-g-
stimulated PBMCs and CD14
+ monocytes/macrophages
from patients with Lyme arthritis
The patterns of chemokine secretion from PBMCs or
CD14
+ monocytes/macrophages from the 4 normal con-
trol subjects were similar to those from the 24 patients
with Lyme arthritis. However, the larger number of
patients tested allowed a clearer picture of the differ-
ences between B. burgdorferi- or IFN-g-stimulated cells.
Unstimulated PBMCs from the 24 patients secreted
basal levels of CXCL9, CXCL10, CCL2, or CCL4 during
5 days in culture, except in rare cases (Figure 2a). In
comparison, B. burgdorferi stimulation of PBMCs
resulted in the secretion of CCL4 and CCL2, and B.
burgdorferi and IFN-g each stimulated the production of
CXCL9 and CXCL10. These differences among stimu-
lated and unstimulated cells were statistically significant
(P < 0.001) (Figure 2a).
In 14 of the 24 patients, large enough numbers of
PBMCs were available to separate a fraction containing
CD14
+ monocytes/macrophages. With the CD14
+ cell
fraction, B. burgdorferi alone stimulated the secretion of
CCL4; B. burgdorferi and IFN-g together induced CCL2
secretion, and IFN-g alone stimulated the secretion of
CXCL9 and CXCL10 with no additive effect from B.
burgdorferi and IFN-g together (Figure 2b). These differ-
ences among stimulated and unstimulated cells were
statistically significant (P < 0.001) (Figure 2b).
Chemokine secretion by B. burgdorferi- or IFN-g-
stimulated PBMCs and SFMCs
Since the types of cells, their numbers, and their activa-
tion state would presumably be different in SFMCs than
PBMCs, cells from these two sites might respond differ-
ently to stimuli. For this analysis, concomitant PBMCs
and SFMCs were available in 11 of the 24 patients.
Owing to limited numbers of cells, CD14
+ cells were
not separated from SFMCs. Without stimulation,
SFMCs or PBMCs secreted basal levels of CXCL9,
CXCL10, CCL2, and CCL4, except in one case (Figure
3). B. burgdorferi,b u tn o tI F N - g, induced the secretion
of CCL4 and CCL2 from PBMCs and SFMCs, whereas
B. burgdorferi or IFN-g each induced cells from either
compartment to secrete CXCL9 and CXCL10. There
were no significant differences between PBMCs and
SFMCs in the secretion of these chemokines.
CXCR3 and CCR5 expression on T cells in PBMCs and
SFMCs
CXCR3, the receptor for CXCL9 and CXCL10 on T cells,
and CCR5, the receptor for CCL4 on monocytes, dendri-
tic cells, and some T cells, are preferentially expressed in
TH1-like immune responses [7-9]. In 6 of the 11 study
patients in whom concomitant PBMCs and SFMCs were
available, the expression of these receptors on T cells was
determined by flow cytometry (Figure 4a). In these
patients, the percentage of unstimulated T cells expres-
sing CXCR3 or CCR5 was significantly greater in SFMCs
than PBMCs (Figure 4b). With PBMCs, B. burgdorferi or
IFN-g appeared to stimulate greater expression of
CXCR3 or CCR5 compared with unstimulated cells.
With SFMCs, CCR5 expression tended to increase with
both stimuli, but the high expression of CXCR3 was
rarely modulated further by either stimulus. However,
none of the differences between stimulated and unstimu-
lated cells was statistically significant.
Discussion
In an effort to understand how B. burgdorferi stimulates
cells of monocyte lineage to secrete chemokines that are
prominent in the joint fluid of patients with Lyme
arthritis, PBMCs, CD14
+ monocytes/macrophages from
PBMCs, and SFMCs from patients were incubated with
B. burgdorferi or IFN-g or both, and the levels of these
chemokines were measured in culture supernatants.
B. burgdorferi directly stimulated CD14
+ cells to secrete
CCL4, a chemoattractant for monocytes and some T
cells [8]. In addition, we recently demonstrated that
B. burgdorferi induces macrophages directly to secrete
CXCL8, a neutrophil chemoattractant, and CCL3, a che-
moattractant for monocytes, natural killer (NK) cells,
and T cells [20]. These chemokines appear to be impor-
tant in innate immune responses to B. burgdorferi [14].
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stimulate CD14
+ monocytes/macrophages to produce
CCL2, whereas IFN-g alone induced them to secrete
CXCL9 and CXCL10. These chemokines are necessary
for adaptive immune responses to the spirochete [14].
In this study, the efficiency of separation of CD14
+
cells from PBMCs was approximately 80% to 90%. How-
ever, it is unlikely that the CD14
- cells in this fraction
had a functional role in our results. If significant num-
bers of T cells were still present in the CD14
+ fraction,
Figure 1 Secretion of chemokines by peripheral blood mononuclear cells (a) or CD14
+ monocytes/macrophages (b) from four normal
control subjects. Cells were not stimulated, or they were stimulated with Borrelia burgdorferi or interferon-gamma (IFN-g) or both. After 5 days
of incubation, the levels of chemokines were measured in the culture supernatants. Each point represents the value of an individual control
subject. The horizontal bars represent the median values. The highest value for CXCL9 was off the scale and is shown numerically. None of the
differences between groups was statistically significant.
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induced some production of CCL2, CXCL9, and
CXCL10, as was the case with PBMCs. Instead, the
levels of these chemokines were undetectable in B. burg-
dorferi-stimulated, CD14
+ cell cultures. Although
dendritic cells can be generated from monocytes in vitro
by culture with GM-CSF (granulocyte-macrophage col-
ony-stimulating factor) and interleukin-4 [21], these
conditions were not used here. Therefore, it is also unli-
kely that dendritic cells played a significant role in our
Figure 2 Secretion of chemokines by peripheral blood mononuclear cells (a) or CD14
+ monocytes/macrophages (b) from 24 patients
with Lyme arthritis. Cells were not stimulated, or they were stimulated with Borrelia burgdorferi or interferon-gamma (IFN-g) or both. After 5
days of incubation, the levels of chemokines were measured in the culture supernatants. Each point represents the value of an individual patient.
The horizontal bars represent the median values. The highest values for CXCL9 were off the scale and are shown numerically. All significant
differences among stimulated and unstimulated cells are shown in brackets and had a P value of less than 0.001.
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peripheral blood mononuclear cells (PBMCs) or synovial fluid mononuclear cells (SFMCs) from 11 patients with Lyme arthritis. After 5
days of incubation, the levels of chemokines were measured in the cell supernatants. The horizontal bars represent the median values. The
highest values for CXCL9 were off the scale and are shown numerically. With each stimulus, chemokine levels did not differ significantly
between PBMCs and SFMCs.
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Page 7 of 10Figure 4 The expression of the chemokine receptors CXCR3 and CCR5 on unstimulated or Borrelia burgdorferi- or interferon-gamma
(IFN-g)-stimulated peripheral blood mononuclear cells (PBMCs) or synovial fluid mononuclear cells (SFMCs) from six patients with
Lyme arthritis. (a) The flow cytometry data are shown for the PBMCs of one patient. After 5 days of incubation, nonadherent cells were
resuspended, collected, and stained with antibodies. A forward scatter/side scatter (FSC/SSC) gate (R1) was used to exclude dead cells, and a
CD3/CD4 gate (R2) was used to further restrict analysis to T cells. The number of events in each gate per number of events collected or the
percentage of gated cells positive for CXCR3 or CCR5 is indicated on the histograms. (b) The percentages of T cells that were brighter than the
isotype control are shown. The horizontal bars represent the median values. Significant differences between PBMCs and SFMCs are shown in
brackets.
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CD14
+ monocytes/macrophages directly to secrete
CCL2, CXCL9, and CXCL10; other factors, likely includ-
ing IFN-g, were required from other intermediate cells
that were present in PBMCs.
What other cells could be a source of IFN-g or other
factors leading to induction of IFN-g-inducible chemo-
kines? It was previously shown, using PBMCs from nor-
mal human donors, that B. burgdorferi stimulation of
dendritic cells induced NK cells to secrete IFN-g [22].
Moreover, in murine B. burgdorferi infection, CD1 d
presentation of a borrelial glycolipid to NK T cells was
important in the early innate immune response, possibly
a sas o u r c eo fI F N - g [23], and CD1d
-/- mice did not
control the infection as well as their wild-type counter-
parts [24]. In murine cytomegalovirus infection [25] and
in Toxoplasma gondii infection [26], early release of
CCL3 and CCL4 from APCs is vital for the influx of NK
cells into affected tissues, and these cells are an impor-
tant source of IFN-g, which induces macrophages and
dendritic cells to secrete CXCL9 and CXCL10 [27].
Thus, NK cells or NK T cells or both are likely sources
for the initial secretion of IFN-g in Lyme disease. How-
ever, it is not yet known whether these cells play a role
in joint inflammation in patients with Lyme arthritis.
Although we focused here on the role of IFN-g in sti-
mulating CD14
+ monocytes/macrophages to secrete
CXCL9 and CXCL10, other factors and cell types may
be involved in the actual infection. For example, type I
IFNs, particularly IFN-a,m a ya l s oh a v ear o l ei ni n d u -
cing the secretion of these chemokines [28,29]. More-
over, under appropriate conditions, neutrophils secrete a
number of cytokines and chemokines, including type I
IFNs [30,31]. Thus, in human Lyme arthritis, it is possi-
ble that multiple cell types produce multiple IFNs,
which induce cells of monocyte lineage to secrete
CXCL9 and CXCL10, thereby leading to the recruitment
of T effector cells to the joint.
It is not yet known how B. burgdorferi stimulates
monocytes/macrophages to secrete CCL4, nor is it clear
how spirochetes in the presence of IFN-g induce CCL2
expression. B. burgdorferi is known to activate mono-
cytes/macrophages through multiple types of receptors
[32-36]. The spirochete is composed of many lipopro-
teins, which presumably stimulate macrophages through
the Toll-like receptor-1 (TLR1)/TLR2 heterodimer
[32,33]. However, live B. burgdorferi,a su s e dh e r e ,
induces monocyte activation by both TLR2-dependent
and TLR2-independent pathways [34-36]. Moreover,
TLR2 ligation is not involved in the secretion of the
IFN-g-inducible chemokines CCL2, CXCL9, and
CXCL10 [37].
Without stimulation, the percentage of cells expres-
sing CXCR3 and CCR5 was significantly greater in
SFMCs than PBMCs, confirming that TH1e f f e c t o rc e l l s
were recruited to the site of a TH1 inflammatory
response in affected joints [12,13]. Consistent with this
result, cells expressing CXCR3 and CCR5 were found
previously in synovial tissue in patients with Lyme
arthritis or rheumatoid arthritis [14,38]. In comparison
with unstimulated cells, there were no significant
changes in the expression of these receptors after stimu-
lation with B. burgdorferi or IFN-g. Moreover, although
SFMCs probably contained a larger percentage of acti-
vated cells, PBMCs and SFMCs responded similarly to
B. burgdorferi and IFN-g in cell cultures.
Conclusions
B. burgdorferi activates monocytes/macrophages directly
to secrete a number of chemokines, including CCL4,
which are important in innate immune responses both
early and late in Lyme disease. At the same time, spiro-
chetes stimulate other intermediate cells, possibly NK or
NK T cells, to produce IFN-g or other factors, which
then induce innate immune cells to secrete CCL2,
CXCL9, and CXCL10, thereby serving as a bridge
between innate and adaptive immune responses. We
conclude that B. burgdorferi stimulates monocytes/
macrophages directly and indirectly to guide innate and
adaptive immune responses in patients with Lyme
arthritis.
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